Elucidating the neuroinflammatory modulatory mechanisms of Maixuekang capsule via network pharmacology and proteomics
Basic science / pharmacology published in Dev Neurobiol (2026)
Abstract
Ischemic stroke is a prominent cause of morbidity and mortality, affecting numerous people worldwide. The exact role of Maixuekang capsule in cerebral ischemia/reperfusion injury (CI/RI) remains elusive. The present study aimed to delve into the neuroprotective potential of Maixuekang in CI/RI rats. Utilizing the HREB database, leech ingredients were retrieved, while GeneCards, therapeutic target database (TTD), and DisGeNET databases were used to predict cerebral infarction targets. Search tool for the retrieval of interacting genes/proteins (STRING) database was adopted to identify overlapping genes, and Cytoscape 3.9.1 to analyze core targets. The gene ontology (GO)/ Kyoto encyclopedia of genes and genomes (KEGG) pathway were analyzed and neurological function was assessed via Longa scoring. The 2,3,5-triphenyltetrazolium chloride (TTC), Golgi, hematoxylin and eosin (H&E), and Nissl stains were adopted to observe cerebral infarction and pathological changes. The neuronal apoptosis, hypoxia inducible factor 1 alpha (HIF1A), myeloperoxidase (MPO) and inflammatory factors in rat were measured. Results suggested Maixuekang reduced the neurological function score and the cerebral infarction incidence in CI/RI rats. After taking Maixuekang, the number of dendritic spines of CI/RI rats increased, the neuronal damage degree in the ischemic cortical area reduced, and the neurons morphology improved. In addition, Maixuekang reduced the blood-brain barrier (BBB) damage and brain tissue water content by decreasing neuronal apoptosis rate, Bax expression, neutrophil infiltration, inflammatory factor levels, and increasing Bcl2 by decreasing HIF1A in CI/RI rat tissues. Collectively, Maixuekang could reduce neurological function, cerebral infarction rate, blood-brain barrier damage, neuroinflammation and downregulates HIF1A in tissues of CI/RI rats.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Network-pharmacology and proteomics elucidation of Maixuekang capsule (containing leech ingredient) neuroinflammatory modulatory mechanisms.
Por qué esto importa para la hirudoterapia
Este estudio empleó bases de datos de farmacología de redes —incluidas HREB, GeneCards, TTD, DisGeNET y STRING— para investigar el potencial neuroprotector de la cápsula Maixuekang en ratas con lesión por isquemia/reperfusión cerebral. El resumen señala que se obtuvieron ingredientes de sanguijuela a partir de la base de datos HREB como parte del análisis de las dianas terapéuticas de la cápsula. Los resultados sugirieron que Maixuekang redujo las puntuaciones de función neurológica, el infarto cerebral, el daño de la barrera hematoencefálica y la neuroinflamación en tejidos de ratas con CI/RI. La conexión con ingredientes de sanguijuela hace que sea tangencialmente relevante para el dominio de la ASH, aunque el estudio examina una cápsula multi-ingrediente en lugar de secreciones aisladas de sanguijuela o hirudoterapia activa. Además, el trabajo se limita a un modelo animal y no establece eficacia clínica.
Citación
Elucidating the neuroinflammatory modulatory mechanisms of Maixuekang capsule via network pharmacology and proteomics.
Han et al. · Developmental neurobiology, 2026
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026